



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Linschoten et al.  
 Serial No. : 09/600,661  
 Filed : July 20, 2000  
 For : PYRIDINE MERCAPTO CARBOXYLIC ACIDS  
 AS CARBOXYPEPTIDASE U INHIBITORS (as  
 amended herein)  
 Examiner : T. McKenzie  
 Group Art Unit : 1624

Certificate of Mailing Under 37 C.F.R. § 1.8	
I hereby certify that this paper is being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
Richard J. Sterner	35,372
Agent Name	PTO Reg. No.
<i>Richard J. Sterner</i>	September 13, 2004
Signature	Date of Signature

**Mail Stop Amendment**

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In compliance with 37 CFR §1.56 and in accordance with  
 37 CFR §§1.97 and 1.98, it is requested that the thirteen (13)  
 references listed on the attached Form PTO/SB/08A be made of  
 record in this application. Copies of the references are  
 enclosed.



In accordance with 35 CFR §§1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information is material to patentability as defined in 37 CFR §1.56(b).

All of the references provided herewith were cited by Applicants in the accompanying Amendment and Response in support of their arguments against the Examiner's rejection of the claims on the grounds of nonenablement. These documents are submitted under 35 CFR §1.97(c), i.e., before the mailing date of a final Action. Accordingly, the Commissioner is hereby authorized to charge the required fee under 37 CFR §1.17(p) to Deposit Account No. 23-1703. Any other fee which may be due for any reason may likewise be charged.


Dated: September 13, 2004

Respectfully submitted,

Richard J. Sterner  
Reg. No. 35,372  
Agent for Applicants

Customer No. 007470  
White & Case LLP  
Direct Dial: (212) 819-8783

Enclosures

**1103326-0631**

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/600,661	
			Filing Date	July 20, 2000	
			First Named Inventor	Linschoten et al.	
			Art Unit	1624	
			Examiner Name	T. McKenzie	
Sheet	1	of	1	Attorney Docket Number	1103326-0631

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		HIRSH, et al., CHEST 2001; 119:1S-2S	
		GEERTS, et al., CHEST 2001; 119:132S-175S	
		ALBERS, et al., CHEST 2001; 119:194S-206S	
		CAIRNS, et al., CHEST 2001; 119:228S-252S	
		ALBERS, et al., CHEST 2001; 119:300S-320S	
		COHEN, Seminars in Thrombosis and Hemostasis 28, suppl. 3, 13-17 (2002)	
		BARROW et al., J. Med. Chem. 46, 5294-5297 (2003)	
		MUTO et al., Eur. J. Pharmacol. 461, 181-189 (2003)	
		SUZUKI et al., J. Pharmacol. Exper. Ther. 309, 607-615 (2004)	
		HASHIMOTO et al., Thromb. Haemost. 87, 110-113 (2002)	
		WU et al., Thromb. Haemost. 90, 414-421 (2003)	
		NAGASHIMA et al., Thromb. Res. 98, 333-342 (2000)	
		REDLITZ et al. Circulation 93, 1328-1330 (1996)	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.